Actively Recruiting
Phase I Open-Label Study of GC203 Engineered Tumor Infiltrating Lymphocytes Therapy for Adults with Advanced Solid Tumors
Led by Shanghai Juncell Therapeutics · Updated on 2026-08-05
8
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of GC203 tumor infiltrating lymphocytes TIL therapy in adults with advanced solid tumors that have not responded to standard treatments. This Phase I, open-label, single-arm trial focuses on patients aged 18 to 75 years with solid tumors who have a life expectancy of more than three months and an ECOG performance status of 0-1. Participants undergo tumor resection to obtain samples for producing the gene-edited GC203 TIL therapy. After preparing the TILs outside the body, participants receive a lymphodepletion treatment followed by an infusion of the engineered GC203 TIL cells. The study monitors adverse events for six months and tracks long-term outcomes such as tumor response, disease control, progression-free survival, and overall survival for up to 36 months. Throughout the study, participants will be closely monitored for safety and treatment effects. Evaluations include measuring tumor lesions, recording any side effects, and assessing overall health status. Participants must have at least one measurable tumor lesion and are followed from treatment through long-term outcome assessments, with the study completion expected by late 2028.
CONDITIONS
Brief Title
A Study of GC203 TIL in Advanced Solid Tumors (NF)
Research Team
Y
Ying Cheng
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here